

Antigen-experienced CXCR5⁻ CD19^{low} B cells are plasmablast precursors expanded in SLE

Franziska Szelinski^{1,2}, Ana Luisa Stefanski¹, Annika Wiedemann¹, Eva Schrezenmeier^{1,3,4}, Hector Rincon-Arevalo^{1,2,3,6}, Karin Reiter^{1,2}, Marie Lettau^{1,2,†}, Van Duc Dang^{1,2}, Sebastian Fuchs⁵, Andreas P. Frei⁵, Tobias Alexander^{1,2}, Andreia C. Lino^{1,2,*} and Thomas Dörner^{1,2,*}

¹Department of Rheumatology and Clinical Immunology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute of Health (BIH), Berlin, Germany

²German Rheumatism Research Center Berlin (DRFZ), a Leibniz Institute, Berlin, Germany

³Department of Nephrology and Intensive Medical Care, Charité- University Medicine Berlin, Berlin, Germany.

⁴Berlin Institute of Health (BIH)

⁵Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland.

⁶Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Instituto de Investigaciones Médicas, Universidad de Antioquia UdeA, Medellín, Colombia.

* ACL and TD contributed equally

Corresponding Author:

Thomas Dörner, MD

Deutsches Rheumaforschungszentrum (DRFZ) Berlin and Department of Medicine/Rheumatology and Clinical Immunology Charite Universitätsmedizin Berlin, Germany.

Chariteplatz 1, 10117 Berlin, Germany

Email: thomas.doerner@charite.de

†Present address: Marie Lettau, Institute of Functional Anatomy, Charité Universitätsmedizin Berlin, Germany

Keywords: DN B cells, systemic lupus erythematosus, CXCR5, atypical B cells, BCR, BNT162b2

1 Abstract

2 B cells play a critical role in the pathogenesis of systemic lupus erythematosus
3 (SLE). We analysed two independent cohorts of healthy donors and SLE patients
4 using a combined approach of flow and mass cytometry. We have found that IgD⁻
5 CD27⁺ switched and atypical IgD⁻CD27⁻ memory B cells, which are increased in SLE,
6 represent heterogeneous populations composed each of three different subsets,
7 such as CXCR5⁺CD19^{int}, CXCR5⁻CD19^{high} and CXCR5⁻CD19^{low}. Here, we
8 characterize a hitherto unknown antigen-experienced CXCR5⁻CD19^{low} B cell subsets
9 enhanced in SLE and carrying a plasmablast (PB) phenotype enriched for switched
10 immunoglobulins, and expressing CD38, CD95, CD71, *PRDM1*, *XBP-1*, and *IRF4*.
11 CXCR5⁻CD19^{low} resemble activated B cells with a characteristically diminished B cell
12 receptor responsiveness. CXCR5⁻CD19^{low} B cells increased with PB frequencies in
13 SLE and upon BNT162b2 vaccination suggesting their interrelationship. Our data
14 suggest that CXCR5⁻CD19^{low} B cells are precursors of plasmablasts, thus co-
15 targeting this subset may have therapeutic value in SLE.

16 Introduction

17 Various abnormalities of the B cell lineage have been identified in systemic lupus
18 erythematosus (SLE), a chronic autoimmune disease characterized by autoantibody
19 production and pathogenic autoimmune complex formation. Abnormalities include
20 increased peripheral plasmablasts (PB)¹, including expanded IgG and IgA producers²
21 as well as altered composition of the B cell compartment with increased frequencies
22 of IgD⁻CD27⁺switched and atypical IgD⁻CD27⁻ memory B cells. How these
23 observations are related remains unclear. Increased switched memory or IgD⁻CD27⁻ B
24 cells were found in rheumatic diseases such as SLE³ and RA^{4, 5, 6} as well as in
25 peripheral blood or tissue in various inflammatory diseases, such as chronic
26 inflammatory bowel⁷ or Alzheimer's disease⁸.

27 In SLE, expansion of switched memory and IgD⁻CD27⁻, (also called double negative,
28 DN) B cells, are features of patients with chronic inflammatory diseases. This shift in
29 the B cell distribution is not seen in new onset patients even though their B cell
30 distribution also differs from healthy donors (HD)⁹. These observations emphasize
31 that enlargement of switched memory and DN B cells are an important characteristic
32 of chronic inflammation⁹. In lupus nephritis (LN), a severe complication of SLE, DN B
33 cells correlated with 24-h urine protein excretion and inversely with glomerular
34 filtration rate¹⁰. Interestingly, this population was found diminished in LN patients
35 during remission suggesting their potential pathogenic involvement and raising the
36 possibility that DN B cells can serve as a prognostic biomarker in lupus nephritis¹⁰.

37 More recently, it became evident that DN B cells represent a heterogeneous subset,
38 including age-/autoimmune-associated B cells (ABCs)^{11, 12, 13}, Syk⁺⁺ B cells¹⁴ and
39 double negative 2 (DN2: IgD⁻CD27⁻CXCR5⁻CD11c⁺) populations¹⁵. All these subsets
40 share partially overlapping characteristics and are linked to disease activity and
41 autoantibody formation. Besides these alterations of B cell subsets residing among
42 DN B cells, impaired chemokine receptor expression¹⁶ and reduced responsiveness
43 upon BCR stimulation^{17, 18, 19} have been reported for these B cells in patients with
44 SLE suggesting their distinct involvement in chronic autoimmunity.

45 This study further delineates the heterogeneity of switched memory (mem) and DN
46 memory B cells in healthy donors and SLE patients. Using a combined flow and
47 mass cytometry approach, we identified an enhanced CXCR5⁻CD19^{low} B cell subset
48 in the switched memory and DN compartments (mem^{low} and DN^{low}) in SLE carrying

49 distinct functional characteristics of antigen-experienced B cells distinct from
50 previously known CXCR5⁺CD19^{int} (mem^{int} and DN^{int}) and CXCR5⁻CD19^{high} (mem^{high}
51 and DN^{high}) B cells which showed a close relationship with peripheral PB. Our data
52 provide multiple new insights, including B cell differentiation abnormalities in SLE
53 relevant for therapeutic considerations targeting B cells in SLE.

54 Material and methods

55 **Patients.** Peripheral blood was obtained from 79 SLE patients meeting the SLICC
56 criteria and from 70 healthy individuals. All study participants gave written consent to
57 participate in this cross-sectional study which was approved by the ethics' committee
58 of the Charité Berlin.

59 **Antibodies.** See Supplementary table 2 for antibodies used for flow cytometry
60 analysis and Supplementary table 3 for antibodies used for mass cytometry analysis.

61 **Whole blood stainings.** Erytholysis of EDTA anticoagulated blood was performed
62 according to manufacturer's protocol using Pharm Lyse (BD). FcR blocking reagent
63 (Miltenyi Biotec) was added to cell suspension before cells were stained for CD3,
64 CD14, CD20, CD19, CD27, IgD, CD38, CD95 and CXCR5. Frequencies of cells were
65 determined using a BD Canto II cytometer.

66 **Peripheral blood mononuclear cells (PBMCs) isolation and cryopreservation.**
67 PBMCs were isolated from EDTA anticoagulated whole blood for flow cytometry
68 stainings and stimulation experiments. Li-Hep-anticoagulated blood was used for
69 CyTOF analysis. Therefore, whole blood was diluted in PBS (Biochrom), layered over
70 Ficoll-Paque PLUS (GE Healthcare Bio-Sciences) and centrifuged. PBMCs were
71 harvested and washed twice with PBS before cell counting. PBMCs were processed
72 immediately or cryopreserved for CyTOF analysis. For this, up to 10x10⁶ PBMCs
73 were diluted in 1:10 DMSO in FBS and cooled down to -80°C using CoolCell Cell
74 Freezing Container (Biocision) before storing at -80°C until further analysis.

75 **Viability assay for discrimination of live and dead cells.** PBMCs were labelled
76 with Blue fluorescent reactive dye (Molecular Probes Invitrogen) 1:1000 in PBS
77 according to the manufacturer's recommendation and washed with PBE. Live/dead
78 stained PBMCs were directly suspended in cold MACS rinsing buffer (with BSA;
79 Miltenyi Biotec) for phenotyping or in pre-warmed RPMI 1640 (with GlutaMAX, Life
80 Technologies) for BCR stimulation assays.

81 **Backbone surface staining of PBMCs for subset identification and**
82 **phenotyping.** Viability labelled cells were pre-treated with FcR blocking reagent
83 (Miltenyi Biotec) for 5 min before being stained with anti-CD19, CD27, CD38, IgD,
84 CD14, CD13, CD10, CD24, CD11c and CD95 as backbone staining and for
85 phenotyping in addition with anti-CD71, -PD1 and -PD-L1. Median fluorescence
86 intensities (MFIs) or frequencies of positive cells were determined using BD LSR
87 Fortessa x-20 (Beckton Dickinson).

88 **Heat map of foldchange.** To evaluate expression of surface marker of subsets in
89 comparison to expression levels on the main B cell populations, \log_2 (fold changes) of
90 median FI or frequencies from the flow cytometry data were plotted as heat map.

91 **Staining for immunoglobulin isotypes.** Viability labelled cells were stained with
92 anti-CD19, CD20, CD27, CD38, CD14, CD13, CD95, CXCR5, IgD, IgM, IgG and IgA.
93 Data was obtained using BD LSR Fortessa x-20 (Beckton Dickinson). Frequencies of
94 cells positive for the different isotypes were collected.

95 **High-dimensional single-cell proteomics analysis using CyTOF.** Frozen PBMCs
96 were thawed and resuspended at 37°C in 1:10 FCS in IMDM. Further sample
97 processing was done as previously described²⁰. Samples were measured using a
98 Helios mass cytometry instrument (Fluidigm).

99 **Vaccination of healthy individuals with BNT162b2.** B cell subsets of healthy
100 individuals were analyzed before administration, 7, 14, 21 days after first vaccination
101 and 7 days after boost with BNT162b2 (Comirnaty®).

102 **Data analysis and UMAP plotting.** Flow and mass cytometry data were analyzed
103 using FlowJo (version 10.6.1, TreeStar). Flow cytometry data was pre-gated on IgD⁻
104 B cells, down sampled to 59.000 events each per cohort of HD or SLE, respectively
105 and clustered by CXCR5, CD19, CD38, CD27, CD10, CD71, CD95 and IgD using
106 dimension reduction algorithm UMAP²¹ plugin in FlowJo. Mass cytometry data was
107 pre-gated on IgD⁻ B cells excluding plasmablasts, down sampled to 8841 cells and
108 clustered by CXCR5, CD19, CD38, CD27, CD11c and IgM using UMAP plugin. As
109 settings for both UMAPs we selected the Euclidean distance function, nearest
110 neighbour value of 15 and a minimum distance of 0.5.

111 **BCR stimulation for analysis of intracellular phosphorylation.** Cells (3×10^6)
112 stained for viability, blocked and stained with modified backbone surface staining

113 (excluding CD24, CXCR5 but including CD22) and equilibrated for 1h at 37°C in
114 RPMI before stimulation with IgG/IgA/IgM (H+L) F(ab')₂ (15 µg/ml) for 5, 8 or 15 min.
115 For baseline, control cells were incubated for 5 min with RPMI. Adding pre-warmed
116 Lyse/Fix buffer (BD) at the respective time-points stopped the stimulation. After
117 washing Phosflow Perm II Buffer (BD) was added to permeabilize cells overnight at -
118 20°C. Cells were then stained for CD24, CXCR5 and the intracellular targets Syk and
119 pSyk (Y352). To investigate BCR response and phosphorylation kinetics, median FIs
120 of Syk, pSyk (Y352) and CD22 were determined.

121 **Gene expression analysis of B cell subsets.** Isolated PBMCs were enriched for B
122 cells by depleting CD3, CD14 and CD235a via MACS microbeads (Miltenyi Biotec)
123 according to the manufacturer's instruction. Cells were stained with CD19, CD20,
124 CD27, CD38, CD3, CD14, CXCR5 and IgD for sorting. Naïve, pre-switched, total
125 memory and PBs as well as DN^{int}, DN^{low} and DN^{high} subsets were sorted and purity
126 check was performed using Sony Sorter MA900. Cells were counted using
127 MACSquant (Miltenyi Biotec). Cell suspension were spin down, resuspended in HTG
128 lysis buffer at a concentration of 200 cells/µl and stored at -80 °C until further
129 processing by HTG (Tucson, AZ). Samples with less than 28% of counts allocated to
130 positive controls probes, read depth above 750,000 and expression variability above
131 0,094 were analyzed.

132 **Statistical evaluation** Data analysis was performed using GraphPad Prism®
133 (Version 9). Statistical significance was considered for p values less than 0.05 and
134 depicted as follows: * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$. Statistical
135 significance between HD and SLE was determined using two-tailed Mann-Whitney-U
136 (MWU) test. To determine statistical significance between the three populations
137 Kruskal-Wallis-Test (KWT) followed by the Dunn's multiple comparison test was
138 performed. Unless stated otherwise, scatter and bar plots represent means \pm SD and
139 Box-Whisker plots show median and range.

140

141 Results

142 *CD19^{low} memory and double negative B cells are increased in SLE patients*

143 We and others have reported several abnormalities within the B cell compartment in
144 SLE patients suggesting their pathogenic relevance. In this regard, IgD⁻CD27⁻ double
145 negative (DN) B cells especially those co-expressing CD95²² and IgD⁻CD27⁺
146 switched memory B cells are increased in SLE^{1, 3}. Therefore, we analyzed these B
147 cell subsets in further detail (Supplementary Fig. S1) and found that switched
148 memory B cells and DN B cells show a similar pattern regarding expression of
149 CXCR5 and CD19, thus, independent of their CD27 expression. Notably, the
150 expression of these molecules subdivided both compartments into three populations
151 (Fig. 1A, Supplementary Fig. S1A). CXCR5⁺CD19^{int} (mem/DN^{int}) and CXCR5⁻
152 CD19^{high} (mem/DN^{high}) B cells have been previously identified and described in HD
153 and SLE with increased frequencies of the CXCR5⁻CD19^{high} fraction in SLE¹⁵. Here,
154 we identified a novel B cell subset within both switched memory B cells and DN B
155 cells that is CXCR5⁻CD19^{low} (mem/DN^{low}).

156 We found that DN^{low} B cells are significantly increased among CD19⁺ B cells in SLE
157 compared to HD (Fig. 1A). While only mem^{high} B cells were increased in the switched
158 memory compartment, all of the three subsets within the DN fraction were
159 significantly increased in SLE patients (Fig. 1B). DN B cells were enriched for
160 CXCR5 negative CD19^{low} and CD19^{high} B cell subsets compared to the CD27⁺ (mem)
161 compartment and in general remarkably expanded in SLE (Fig. 1 C). Next, we
162 applied the dimension reduction algorithm UMAP²¹ to cluster IgD⁻ B cells. Using this
163 approach, we identified mem/DN CD19^{int}, mem/DN^{high} and mem/DN^{low} as distinct
164 populations (Fig. 1D). In this UMAP, both CD19^{low} populations clustered together with
165 CD27⁺⁺CD38⁺⁺ PB (Fig. 1D). Comparison of the clusters obtained from HD with SLE
166 patients revealed an increased density of the corresponding subsets in SLE (Fig.
167 1E), consistent with their significant expansion in this condition.

168 *CD19^{low} B cell subsets display a plasmablast-like phenotype*

169 Next, we characterized DN^{int}, DN^{high} and DN^{low} B cell subsets for the expression of
170 several surface molecules including lineage, differentiation and activation markers.
171 The resulting expression patterns of CD27, CD19, CXCR5, CD24, CD71, CD95,
172 CD38 and CD11c is visualized by colour code in the dimension reduced UMAP (Fig.
173 2A). With this analysis, we found that the subsets defined by their distinct CD19 and

174 CXCR5 expression allowed further differentiation by different expression profiles of
175 CD24, CD71, CD95, CD38 and CD11c among the IgD⁻CD27⁻ subsets (Fig. 2A).

176 We found that CD24, a marker with a dynamic expression pattern throughout B cell
177 maturation and absent in antibody producing cells²³, was not present in both subsets
178 with low CD19 and lacking CXCR5 expression (mem/DN^{low}) in contrast to the DN^{int}
179 population.

180 Besides CD19 expression the main discriminators between the DN^{low} and DN^{high}
181 populations were CD38 and CD11c (Fig. 2A, B). As previously described, DN^{high} are
182 CD11c^{high} but lack CD38 expression^{15, 20}. In contrast, the majority of DN^{low} B cells
183 express CD38 (Fig. 2B, C and Supplementary Fig. 1B). Expression of CD71, a
184 marker for early B cell activation²⁴, was upregulated on the surface of CXCR5⁻
185 CD19^{low} B cells, comparable to levels found on plasmablasts (Fig. 2C). CD95 was
186 expressed by the majority of DN^{low} and DN^{high} cells but not on DN^{int}.

187 Subsequently, we evaluated the expression of inhibitory receptor PD-1 that is
188 upregulated on B cells upon activation^{19, 25} and its ligand PD-L1. Surface expression
189 of PD-L1 and PD-1 was only found enhanced in DN^{high} (Fig. 2D, Supplementary Fig.
190 1C).

191 Most noteworthy, each of the subsets of DN differed from the corresponding subsets
192 in the switched memory compartment mainly by the expression of CD27 while the
193 other makers were expressed in a similar pattern (Fig. 2E, Supplementary Fig. 1).
194 This, suggesting that memory and DN population consist of complementary subsets.

195 Comparison of the newly identified subsets with conventional transitional
196 (CD10⁺CD24⁺CD38⁺), naïve (IgD⁺CD27⁻) or pre-switched memory (IgD⁺CD27⁺) B
197 cells and PB (CD27⁺⁺CD38⁺⁺) demonstrated that mem/DN subsets are similar to PB,
198 expressing comparable levels of CD19, CD24, CD10, CD11c, CD71, PD1, PD-L1
199 and CD95. Main differences between PB and mem/DN^{low} cells were a
200 diminished/absent expression of CD27 and a slightly lower CD38 expression among
201 both mem^{low} and DN^{low} B cell subsets (Fig. 2E). It needs emphasis that the
202 frequencies of mem/DN^{low} B cell strongly correlated with those of PB (Fig. 2F) in SLE
203 patients as well as healthy controls further supporting their potential relationship.

204 Since we saw differences in the frequencies we also checked for qualitative
205 differences between HD and SLE. When comparing expression profiles of the three

206 DN B cell subsets between HD and SLE patients, we found that expression levels of
207 proliferation marker CD71 and frequencies of activation markers CD95⁺ and CD38⁺
208 cells were increased within the DN^{int} (Fig. 2G) but not the mem^{int} (Supplementary
209 Fig.1D) population of SLE patients. The expression of CD71 was enhanced in both
210 DN^{low} and mem^{low} in SLE (Fig. 2G, Supplementary Fig. 1D). Regarding Ig isotype
211 expression, we found that mem/DN^{int} and mem/DN^{high} mainly express IgG while
212 mem/DN^{low} express IgG and IgA to a similar extend. (Fig. 2H).

213 **CD19^{low} B cells are characterized by a distinct activation and differentiation** 214 **profile**

215 Next, we validated our findings in an independent cohort of 27 SLE patients and 18
216 healthy donors using CyTOF including expression of activation markers and
217 checkpoint molecules (Fig. 3, Supplementary Fig. 2). Initially, we confirmed the
218 increased frequency of all three subsets within the DN compartment in SLE patients
219 as shown by the UMAP plot by increased DN^{int}, DN^{high} and DN^{low} clusters (Fig. 3A).
220 Besides the significantly increased DN subsets in patients, mem^{low} B cells were also
221 substantially increased in SLE (Fig. 3B), corroborating the flow cytometry findings
222 noted above.

223 Expression of early activation markers such as CD86, CD69 and CD25, both
224 mem/DN^{low} and mem/DN^{high} were indicative of an activated phenotype with increased
225 CD86 and in case of mem/DN^{high} also increased CD69 expression compared to
226 mem/DN^{int}. In contrast, mem/DN^{high} and mem/DN^{low} populations expressed less
227 CD25 compared to mem/DN^{int} (Fig. 3C).

228 SLE patients expressed more CD86, CD69, and CD25 on the surface of mem^{high} B
229 cells and were characterized by elevated CD86 and CD25 expression on DN^{high}
230 compared to HD. In general, mem/DN^{int} cells of patients with SLE expressed more
231 CD86 and diminished CD25 surface expression (Fig. 3D) indicating their increased
232 activation status.

233 Additionally, we determined CD45RA and CD45RO expression, known to be
234 differentially expressed throughout B cell differentiation^{26, 27}. CD45RA was increased
235 on switched memory B cells compared to DN, but its expression was comparable
236 among the three subsets analyzed (Supplementary Fig. 2 C). When comparing the
237 expression in SLE, we found that CD45RA expression was reduced on DN^{high} cells
238 from patients in comparison with HD (Supplementary Fig. 2 D).

239 Co-stimulatory and co-inhibitory immune checkpoints (CPMs) regulate and modulate
240 immune cells and play an important role in fine tuning the immune response^{20, 28, 29, 30,}
241 ³¹. Therefore, we analyzed the expression profiles of various CPMs among the
242 subsets of interest. Of particular note, mem/DN^{high} upregulated immune checkpoint
243 molecules, such as BTLA, VISTA and CTLA-4 (Fig. 3E, Supplementary Fig. 2 E, F)
244 suggesting a shared functionality. While VISTA and CTLA-4 expression by
245 mem/DN^{low} cells was comparable to the levels found on the mem/DN^{int}, BTLA was
246 downregulated (Fig.3E).

247 SLE patients expressed higher levels of VISTA on mem^{low} B cells (Fig. 3F) but
248 otherwise did not differ from findings in HD. Overall, CD19^{low} B cells showed a
249 strikingly reduced expression of checkpoint molecules independent of their CD27
250 expression.

251 **CD19^{low} subsets correlate with plasmablasts generated in HD upon vaccination** 252 **with BNT162b2**

253 Since mem^{low} and DN^{low} are increased in SLE and correlated with PB, we asked
254 whether an acute immune response resulting in PB formation would be accompanied
255 by alterations and expansion of those subsets in HD. Therefore, we monitored B cell
256 subsets in HD on day 0, 7, 14 and 21 after single-dose administration of BNT162b2
257 vaccine and 7 days after boost (Fig. 4A). Of particular note, this vaccine is able to
258 elicit a striking T cell dependent immune activation³². As a result, the frequencies of B
259 cell subsets did not change significantly except reduction of mem^{int} and DN^{int} on day
260 21 after vaccination compared to day0 and day 7, respectively. Although not
261 significant, a trend of increased plasmablast formation was detected at day 7 after
262 boost (Fig. 4A). Of particular note, frequencies of mem^{low} B cells correlated strikingly
263 with PB on day 21 and 7 days after boost. DN^{low} B cells also showed a correlation
264 with PB 7 days after boost (Fig. 4B). These findings supported further that mem^{low}
265 and DN^{low} expansion follows kinetics of PB induction and depends on T cell
266 instruction as evidenced by BNT162b2 vaccination.

267 **CD19^{low} subsets present with reduced BCR responsiveness**

268 To evaluate B cell receptor responsiveness of newly identified subsets as a read-out
269 for their functional competence, we studied phosphorylation kinetics of Syk (Y352)
270 upon anti-BCR stimulation (Fig. 5A). We observed diminished Syk phosphorylation in
271 the DN compartment compared to subsets of switched memory B cells. In both

272 switched memory and DN B cells, subsets with low CD19 expression showed lowest
273 pSyk kinetics while CD19^{int} and CD19^{high} subsets respond similarly to BCR
274 stimulation. The BCR responsiveness was significantly reduced among mem^{int} and
275 mem^{high} from patients with SLE five to eight minutes after stimulation. While there
276 was an overall lower phosphorylation in B cells from SLE patients, both mem/DN^{low}
277 subsets from SLE patients showed a BCR response kinetics as found for
278 CD27⁺⁺CD38⁺⁺ plasmablasts (Fig. 5A).

279 Subsequently, we evaluated whether differences in Syk protein levels in steady state
280 may account for this difference between subsets and SLE vs HD (Fig. 5B). We found
281 that basal Syk levels were highest in mem/DN^{high}. SLE patients showed significantly
282 decreased Syk levels in mem^{low} B cells. Interestingly, Syk expression was
283 comparable in mem/DN^{low} subsets compared with mem/DN^{int} cells (Fig. 5A,B).

284 ***PRDM1, XBP1, IRF4 and EZH2* upregulation in CD19^{low} B cells suggests a** 285 **plasmablast-like transcriptional program**

286 To further understand the distinct nature of the analyzed B cell subsets,
287 transcriptome analysis was performed on naive, pre-switched, total memory (IgD⁻
288 CD27⁺), DN^{int}, DN^{high}, DN^{low} and PBs of patients with SLE and HD (Fig. 6).
289 Transcripts of IRF4 a transcription factor crucial for differentiation³³ and survival³⁴ of
290 plasmablast and plasma cell was not only upregulated in plasmablast but also
291 increased in DN^{low} cells. IRF4 is known to regulate Blimp-1 (encoded by *PRDM1*)
292 expression a regulator of plasma cell differentiation³⁵. The median transcription level
293 of *PRDM1* was found increased in DN^{low} cells. Consistently, mRNA levels of *Pax5*, a
294 transcription factor downregulated by Blimp-1, was found intermediately decreased,
295 while *XBP1* and *EZH2* showed a slightly higher expression level among DN^{low} B
296 cells. No changes occurred for *BCL2L1* expression as a marker for GC
297 differentiation³⁶. Thus, there was an overall trend of key transcription factors defining
298 B cells and PB indicating that the DN^{low} population carries the transcriptional program
299 closely related to PB.

300 Discussion

301 Herein, we identified two novel CXCR5⁻CD19^{low} populations, mem^{low} and DN^{low},
302 residing within conventional switched memory and IgD⁻CD27⁻ atypical memory B
303 cells, respectively. Additionally, we found a not yet described CXCR5⁻CD19^{high}
304 population in switched memory B cells (mem^{high}) which shared characteristics, such

305 as CD11c⁺ expression, with the previously reported DN2¹⁵. The DN2 population
306 corresponds to the DN^{high} population which is further characterized here and has
307 been described as precursor of antibody secreting plasmablasts generated by
308 extrafollicular activation, and found to be increased in autoimmune
309 conditions such as SLE¹⁵ but also acute viral infections such as SARS-CoV-2³⁷. The
310 expression profile of CD19^{high}, CD38⁻, CD95⁺ and Ki-67 together with the high BCR
311 responsiveness and increased Syk expression also suggest that mem/DN^{high}
312 represent the previously described Syk^{high} population¹⁴.

313 Although various groups reported an overall reduction of CD19 expression on B cells
314 in SLE, a specific CD19^{low} population has not been characterized so far. In the study
315 by Culton *et al.*³⁸, the SLE cohort was subdivided into CD19^{lo} and CD19^{hi} patients
316 based on global CD19 expression and the presence or lack of a CD19^{hi} B cell
317 population. Autoantibodies were detected in both patient groups. The majority of the
318 CD19^{low} B cells were described as IgD⁺, CD38⁺, and CD27⁻. Additionally, a decrease
319 in CD19 expression on B cells was reported in anti-neutrophil cytoplasmic
320 autoantibody associated small vessel vasculitis (ANCA-SVV) patients, suggesting
321 that downregulation of CD19 might be a common feature of antibody driven
322 disease³⁸. Other studies reported lower CD19 expression in CD27⁻ but also in CD27⁺
323 B cells^{39, 40}. These studies did not discriminate populations based on their IgD
324 expression. Overall decrease of CD19 expression was seen in both active³⁹ and
325 quiescent⁴⁰ patients with SLE and also in patients with ANCA-SVV, suggesting
326 variation in CD19 expression as an intrinsic abnormality linked to autoimmunity rather
327 than driven by antigen specificity or disease severity.

328 We found that CD19^{low} B cell subsets, mem^{low} and DN^{low} expressed co-stimulatory
329 molecule and activation marker CD86, proliferation marker CD71⁴¹ and the majority
330 were CD38⁺ and CD95⁺ while early B cell stage marker CD24⁴² and CD10⁴³ were
331 absent. In combination with surface expression of class switched immunoglobulins
332 IgG and IgA allows the conclusion that mem/DN^{low} B cells were antigen experienced.
333 Although, Syk itself was not reduced, phosphorylation kinetics of Syk upon anti-BCR
334 stimulation were lower in DN^{low}, similarly to PB. This could be caused either by an
335 anergic post- activation phenotype similar to the one seen in general naïve and
336 memory B cells of patients with autoimmune conditions like SLE, RA and pSS¹⁸. An
337 alternative explanation would be the downregulation of the BCR including BCR-
338 associated surface molecules like negative regulator BTLA which we found

339 downregulated in mem/DN^{low} cells. Increased frequencies of the BTLA low
340 expressing DN^{low} population in SLE could explain the reduced BTLA expression as
341 recently reported for the overall DN population in patients with SLE²⁸.

342 Interestingly and in alignment with our findings, Ruschil *et al.*⁴⁴ recently found that
343 transcripts from total DN cells did not cluster separately from the other cell
344 populations but instead clustered donor dependent with naïve, memory or
345 plasmablasts. They found the number of identified differentially expressed genes was
346 low between plasmablasts and total DN B cells⁴⁴. In this context, our study detected
347 that mem/DN^{low} populations clearly correlated with PBs in SLE and immune
348 challenged HD upon vaccination with BNT162b2. In addition, targeted RNAseq
349 analysis demonstrated an upregulated plasmablast-like transcriptional programming
350 in DN^{low}. Although further studies are needed to evaluate those findings for the
351 mem^{low} population, the current data support that mem/DN^{low} cells are a unique
352 subset carrying characteristics of PB destiny.

353 The fact that we found similar subsets in both the switched memory and DN B cell
354 compartment was unexpected. While the double negative population is known for its
355 heterogeneity and two of the three populations are part of the DN domain, we found
356 shared characteristics with previously reported subsets^{14, 15}. Of note, not so much is
357 known about the diversity of the CD27⁺ memory compartment beyond Ig isotype
358 distribution.

359 The features of the three subsets were comparable between corresponding subset in
360 IgD⁻CD27⁺ switched and IgD⁻CD27⁻ atypical memory B cells supporting the idea that
361 the increase of DN B cells in chronic immune conditions can also be largely related to
362 loss of CD27 expression⁴⁵ which is supported by their comparable increase in SLE
363 and in particular by lack of CXCR5 expression. The latter can result from their a)
364 post-GC b) extrafollicular or c) activation status also known to be related with CD27
365 shedding including increased solubleCD27 in autoimmune diseases^{45, 46}.

366 It is widely known that B cell homeostasis is altered in patients with SLE and B cell
367 targeted interventions are promising in this disease. However, the heterogeneity of
368 the switched memory and DN populations is only partially understood, and it remains
369 unclear how it is induced and/or maintained or how it contributes to the course of the
370 disease. Using CD19 and CXCR5 clearly allows the differentiation of switched
371 memory and DN B cells not only into three distinct subsets each but also suggest

372 that mem/DN^{low} are direct precursors of plasmablasts, while mem^{int} and DN^{int} appear
373 to belong to the B memory compartment. With new compounds targeting B cells in
374 the pharmaceutical pipeline, it is important to understand the mechanisms of how B
375 cells subsets are driving the disease and require consideration by innovative
376 therapies. Our data suggest that the CXCR5⁻ populations might not be targeted by
377 anti-CXCR5 and anti-CD19 strategies but might benefit from anti-CD38 and anti-
378 BAFF therapies. For belimumab, which targets early, transitional B cells and partially
379 PB/PC^{47, 48}, recent studies could document that blocking BAFF/BLyS by belimumab
380 had rapid effects on B cell subsets of earlier developmental stages such as naïve B
381 cells. Late B cell stages, such as memory or plasma cells, decreased later in a
382 gradual manner or did not change upon treatment. Only early immunological
383 changes correlated with disease improvement⁴⁹ These data together with our study
384 provide a rationale for modalities that target naïve and early B cell stages and may
385 thereby prevent not only their differentiation into memory B cells but also their direct
386 path becoming plasmablasts/plasma cells.

387 Collectively, the data presented here, including surface marker expression,
388 correlation analysis, BCR kinetics and transcription analysis strongly indicate that
389 mem/DN^{low} cells are precursors of PB and directly contribute to plasmacytosis upon
390 immune activation. These mem/DN^{low} cells reflect a subset of pre-plasma cells that
391 may not require to undergo full or incomplete memory B cell differentiation.
392 Understanding of the involved selection mechanisms will be important not only in
393 terms of their immunobiological features but also for potential treatment strategies. In
394 this regard, the current data suggest that there could be selective treatment
395 approaches not only for certain B cell subsets but also distinct PB/PC compartments,
396 including the possibility to leave protective PB/PC untouched.

397

398 **Acknowledgment**

399 We thank S. Gaertner, D. Hurd and M. Rastegar from HTG Molecular Diagnostics,
400 Inc. and J. Kirsch, T. Kaiser from the Flow Cytometry Core Facility of the DRFZ.

401 **Author Contributions**

402 The theoretical framework was developed by FS, ACL and TD.

403 Data were obtained by FS, ALS, ES, HR-A, AW, KR, ML, VDD, AF and SF.

404 Data were analyzed by FS, ACL.

405 All authors developed, read, and approved of the current manuscript.

406 **Conflict of Interest Statement**

407 The authors declare that the research was conducted in the absence of any
408 commercial or financial relationships that could be construed as a potential conflict of
409 interest.

410 **Funding**

411 This work was supported by DFG grants project Do491/7-5, Do491/10-1, Do491/11-
412 1, TR130 project 24 and LI3540/1-1. The DRFZ, a Leibniz Institute was supported by
413 the Senate of Berlin. ALS is supported by DGRh Research Initiative 2020. ES was
414 supported by a Fellowship of the Berlin Institutes of Health and received a grant from
415 the Federal Ministry of Education and Research (BMBF) (BCOVIT, 01KI20161). HR-
416 A was supported by COLCIENCIAS scholarship No. 727, 2015.
417 Prof. Dörner was granted the HTG EdgeSeq 2020 Autoimmune Panel Research
418 Grant Award for transcriptome analysis using the Immune Response Panel.

419 **Ethics Statement**

420 This study was carried out in accordance with the recommendations of the ethics'
421 committee at the Charité University Hospital Berlin with written informed consent
422 from all subjects. All subjects gave written informed consent in accordance with the
423 Declaration of Helsinki.

424 **Availability of data and material**

425 The datasets used and analyzed during the current study are available from the
426 corresponding author on reasonable request.
427

428 **References**

- 429 1. Odendahl, M. *et al.* Disturbed peripheral B lymphocyte homeostasis in
430 systemic lupus erythematosus. *J Immunol* **165**, 5970-5979 (2000).
- 431 2. Mei, H.E. *et al.* Plasmablasts With a Mucosal Phenotype Contribute to
432 Plasmacytosis in Systemic Lupus Erythematosus. *Arthritis Rheumatol* **69**,
433 2018-2028 (2017).

435

- 436 3. Wei, C. *et al.* A new population of cells lacking expression of CD27 represents
437 a notable component of the B cell memory compartment in systemic lupus
438 erythematosus. *J Immunol* **178**, 6624-6633 (2007).
- 439
440 4. Moura, R.A. *et al.* B-cell phenotype and IgD-CD27- memory B cells are
441 affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.
442 *PLoS One* **12**, e0182927-e0182927 (2017).
- 443
444 5. Souto-Carneiro, M.M. *et al.* Alterations in peripheral blood memory B cells in
445 patients with active rheumatoid arthritis are dependent on the action of tumour
446 necrosis factor. *Arthritis Res Ther* **11**, R84 (2009).
- 447
448 6. Floudas, A. *et al.* Pathogenic, glycolytic PD-1+ B cells accumulate in the
449 hypoxic RA joint. *JCI Insight* **5** (2020).
- 450
451 7. Pararasa, C. *et al.* Reduced CD27(-)IgD(-) B Cells in Blood and Raised
452 CD27(-)IgD(-) B Cells in Gut-Associated Lymphoid Tissue in Inflammatory
453 Bowel Disease. *Front Immunol* **10**, 361 (2019).
- 454
455 8. Bulati, M. *et al.* Double negative (IgG+IgD-CD27-) B cells are increased in a
456 cohort of moderate-severe Alzheimer's disease patients and show a pro-
457 inflammatory trafficking receptor phenotype. *J Alzheimers Dis* **44**, 1241-1251
458 (2015).
- 459
460 9. Zhu, L. *et al.* Altered frequencies of memory B cells in new-onset systemic
461 lupus erythematosus patients. *Clinical Rheumatology* **37**, 205-212 (2018).
- 462
463 10. You, X. *et al.* Double Negative B Cell Is Associated With Renal Impairment in
464 Systemic Lupus Erythematosus and Acts as a Marker for Nephritis Remission.
465 *Frontiers in Medicine* **7** (2020).
- 466
467 11. Li, H., Borrego, F., Nagata, S. & Tolnay, M. Fc Receptor-like 5 Expression
468 Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory
469 B Cells. *The Journal of Immunology* **196**, 4064-4074 (2016).
- 470
471 12. Rubtsova, K., Rubtsov, A.V., Cancro, M.P. & Marrack, P. Age-Associated B
472 Cells: A T-bet-Dependent Effector with Roles in Protective and Pathogenic
473 Immunity. *The Journal of Immunology* **195**, 1933-1937 (2015).
- 474
475 13. Cancro, M.P. Age-Associated B Cells. *Annu Rev Immunol* **38**, 315-340 (2020).
- 476
477 14. Fleischer, S.J. *et al.* Increased Frequency of a Unique Spleen Tyrosine Kinase
478 Bright Memory B Cell Population in Systemic Lupus Erythematosus. *Arthritis &*
479 *Rheumatology* **66**, 3424-3435 (2014).

- 480
481 15. Jenks, S.A. *et al.* Distinct Effector B Cells Induced by Unregulated Toll-like
482 Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus
483 Erythematosus. *Immunity* **49**, 725-739.e726 (2018).
- 484
485 16. Yoshikawa, M. *et al.* Type I and II interferons commit to abnormal expression
486 of chemokine receptor on B cells in patients with systemic lupus
487 erythematosus. *Clinical Immunology* **200**, 1-9 (2019).
- 488
489 17. Fleischer, S.J., Daridon, C., Fleischer, V., Lipsky, P.E. & Dörner, T. Enhanced
490 Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor
491 Signaling and Promotes Survival of Human Lupus B Cells. *Arthritis Rheumatol*
492 **68**, 1210-1221 (2016).
- 493
494 18. Weißenberg, S.Y. *et al.* Identification and Characterization of Post-activated B
495 Cells in Systemic Autoimmune Diseases. *Front Immunol* **10**, 2136 (2019).
- 496
497 19. Stefanski, A.L. *et al.* Enhanced Programmed Death 1 and Diminished
498 Programmed Death Ligand 1 Up-Regulation Capacity of Post-Activated Lupus
499 B Cells. *Arthritis Rheumatol* **71**, 1539-1544 (2019).
- 500
501 20. Rincon-Arevalo, H. *et al.* Deep Phenotyping of CD11c+ B Cells in Systemic
502 Autoimmunity and Controls. *Frontiers in Immunology* **12** (2021).
- 503
504 21. McInnes, L. & Healy, J. UMAP: Uniform Manifold Approximation and
505 Projection for Dimension Reduction. (2018).
- 506
507 22. Jacobi, A.M. *et al.* Activated memory B cell subsets correlate with disease
508 activity in systemic lupus erythematosus: delineation by expression of CD27,
509 IgD, and CD95. *Arthritis Rheum* **58**, 1762-1773 (2008).
- 510
511 23. Hunte, B.E., Capone, M., Zlotnik, A., Rennick, D. & Moore, T.A. Acquisition of
512 CD24 expression by Lin⁻CD43⁺B220^{low} cells coincides with
513 commitment to the B cell lineage. *European Journal of Immunology* **28**, 3850-
514 3856 (1998).
- 515
516 24. Ellebedy, A.H. *et al.* Defining antigen-specific plasmablast and memory B cell
517 subsets in human blood after viral infection or vaccination. *Nat Immunol* **17**,
518 1226-1234 (2016).
- 519
520 25. Thibult, M.-L. *et al.* PD-1 is a novel regulator of human B-cell activation.
521 *International Immunology* **25**, 129-137 (2012).
- 522

- 523 26. Jensen, G.S., Poppema, S., Mant, M.J. & Pilarski, L.M. Transition in CD45
524 isoform expression during differentiation of normal and abnormal B cells.
525 *International Immunology* **1**, 229-236 (1989).
- 526
527 27. Jackson, S.M. *et al.* CD45RO enriches for activated, highly mutated human
528 germinal center B cells. *Blood* **110**, 3917-3925 (2007).
- 529
530 28. Wiedemann, A. *et al.* BTLA Expression and Function Are Impaired on SLE B
531 Cells. *Frontiers in Immunology* **12** (2021).
- 532
533 29. Ceeraz, S., Nowak, E.C., Burns, C.M. & Noelle, R.J. Immune checkpoint
534 receptors in regulating immune reactivity in rheumatic disease. *Arthritis Res*
535 *Ther* **16**, 469 (2014).
- 536
537 30. Paluch, C., Santos, A.M., Anzilotti, C., Cornall, R.J. & Davis, S.J. Immune
538 Checkpoints as Therapeutic Targets in Autoimmunity. *Frontiers in immunology*
539 **9**, 2306-2306 (2018).
- 540
541 31. Murphy, K.A. *et al.* Immunomodulatory receptors are differentially expressed
542 in B and T cell subsets relevant to autoimmune disease. *Clin Immunol* **209**,
543 108276 (2019).
- 544
545 32. Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and TH1
546 T cell responses. *Nature* **586**, 594-599 (2020).
- 547
548 33. Sciammas, R. *et al.* Graded expression of interferon regulatory factor-4
549 coordinates isotype switching with plasma cell differentiation. *Immunity* **25**,
550 225-236 (2006).
- 551
552 34. Tellier, J. *et al.* Blimp-1 controls plasma cell function through the regulation of
553 immunoglobulin secretion and the unfolded protein response. *Nat Immunol* **17**,
554 323-330 (2016).
- 555
556 35. Low, M.S.Y. *et al.* IRF4 Activity Is Required in Established Plasma Cells to
557 Regulate Gene Transcription and Mitochondrial Homeostasis. *Cell Rep* **29**,
558 2634-2645.e2635 (2019).
- 559
560 36. Takahashi, Y. *et al.* Relaxed negative selection in germinal centers and
561 impaired affinity maturation in bcl-xL transgenic mice. *J Exp Med* **190**, 399-410
562 (1999).
- 563
564 37. Woodruff, M.C. *et al.* Extrafollicular B cell responses correlate with neutralizing
565 antibodies and morbidity in COVID-19. *Nature Immunology* **21**, 1506-1516
566 (2020).

- 567
568 38. Culton, D.A. *et al.* Similar CD19 dysregulation in two autoantibody-associated
569 autoimmune diseases suggests a shared mechanism of B-cell tolerance loss.
570 *J Clin Immunol* **27**, 53-68 (2007).
- 571
572 39. Sato, S., Hasegawa, M., Fujimoto, M., Tedder, T.F. & Takehara, K.
573 Quantitative genetic variation in CD19 expression correlates with
574 autoimmunity. *J Immunol* **165**, 6635-6643 (2000).
- 575
576 40. Korganow, A.-S. *et al.* Peripheral B cell abnormalities in patients with systemic
577 lupus erythematosus in quiescent phase: Decreased memory B cells and
578 membrane CD19 expression. *Journal of Autoimmunity* **34**, 426-434 (2010).
- 579
580 41. Biselli, R., Matricardi, P.M., D'Amelio, R. & Fattorossi, A. Multiparametric flow
581 cytometric analysis of the kinetics of surface molecule expression after
582 polyclonal activation of human peripheral blood T lymphocytes. *Scand J*
583 *Immunol* **35**, 439-447 (1992).
- 584
585 42. Mensah, F.F.K. *et al.* CD24 Expression and B Cell Maturation Shows a Novel
586 Link With Energy Metabolism: Potential Implications for Patients With Myalgic
587 Encephalomyelitis/Chronic Fatigue Syndrome. *Frontiers in Immunology* **9**
588 (2018).
- 589
590 43. Palanichamy, A. *et al.* Novel human transitional B cell populations revealed by
591 B cell depletion therapy. *Journal of immunology (Baltimore, Md. : 1950)* **182**,
592 5982-5993 (2009).
- 593
594 44. Ruschil, C. *et al.* Specific Induction of Double Negative B Cells During
595 Protective and Pathogenic Immune Responses. *Frontiers in Immunology* **11**
596 (2020).
- 597
598 45. Font, J. *et al.* Elevated soluble CD27 levels in serum of patients with systemic
599 lupus erythematosus. *Clin Immunol Immunopathol* **81**, 239-243 (1996).
- 600
601 46. Swaak, A.J., Hintzen, R.Q., Huysen, V., van den Brink, H.G. & Smeenk, J.T.
602 Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in
603 systemic lupus erythematosus in relation with lymphocytes count and disease
604 course. *Clin Rheumatol* **14**, 293-300 (1995).
- 605
606 47. Benitez, A. *et al.* Belimumab alters transitional B-cell subset proportions in
607 patients with stable systemic lupus erythematosus. *Lupus* **28**, 1337-1343
608 (2019).
- 609

610 48. Jacobi, A.M. *et al.* Effect of long-term belimumab treatment on B cells in
611 systemic lupus erythematosus: extension of a phase II, double-blind, placebo-
612 controlled, dose-ranging study. *Arthritis and rheumatism* **62**, 201-210 (2010).

613
614 49. Ramsköld, D. *et al.* B cell alterations during BAFF inhibition with belimumab in
615 SLE. *EBioMedicine* **40**, 517-527 (2019).

616

617 Figure legends

618 **Figure 1: CD19^{low}CXCR5⁻ B cells are increased in SLE patients. (A)**

619 Representative flow cytometry contour plots of one healthy donor and one SLE
620 patient showing CD19 and CXCR5 expression in IgD⁻CD27⁺ or IgD⁻CD27⁻ B cells. **(B)**

621 Distribution of CD19⁺ B cell frequencies of the six populations CXCR5⁺CD19^{int}
622 (mem^{int}/DN^{int}), CXCR5⁻CD19^{low} (mem^{low}/DN^{low}), CXCR5⁻CD19^{high} (mem^{high}/DN^{high}) of

623 IgD⁻CD27⁺ memory or IgD⁻CD27⁻ DN B cells respectively for HD (n=16, dots) and
624 patients with SLE (n=28, triangles). **(C)** Distribution of subsets within switched

625 memory (IgD⁻CD27⁺) and DN (IgD⁻CD27⁻) in HD (n=16) and SLE (n=28) **(D)** Overlay
626 of UMAP clustering of pre-gated IgD⁻ B cells (59000 events each per cohort of HD or

627 SLE, respectively) and manual gated IgD⁻CD27⁻ subsets. Gates of DN^{int}, DN^{low} and
628 DN^{high} populations are indicated. **(E)** Comparison of UMAP density plots clustering

629 corresponding B cell subsets of HD and SLE. (MWU between selected relevant
630 comparisons: * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$)

631 **Figure 2: Expression patterns of surface markers differ between DN^{low}, DN^{high} 632 and DN^{int} subsets but are comparable to corresponding memory subsets. (A)**

633 Colour coded mean signal intensity of CD27, CD19, CXCR5, CD24, CD71, CD95,
634 CD38 and CD11c presented as UMAP. Gates indicate the clustered areas of DN^{low}

635 (left gate), DN^{high} (middle gate) and DN^{int} (right gate). **(B)** Representative histograms

636 of flow cytometry data of DN subsets of one healthy donor showing surface marker
637 expression in comparison to CD19⁻ cells (grey) and CD27⁺⁺CD38⁺⁺ plasmablasts

638 (black line). **(C)** Box and whisker plots of median FI of CD24, CD11c, CD71 and
639 frequencies of CD38⁺ or CD95⁺ of HD (n=8) for each subset of DN **(D)** and median

640 FIs of PD1 and PD-L1 in HD (n=8).(test: MWU) **(E)** Heat map showing log₂(fold
641 change) of median FI of surface marker expression by mem/DN^{int}, mem/DN^{low} and

642 mem/DN^{high} subsets related to main B cell populations of transitional, naïve
643 (IgD⁺CD27⁻), pre-switched (IgD⁺CD27⁺) and plasmablast (PB). Red indicating

644 markers that are higher expressed on the subsets of interest and blue indicating a
645 lower expression of the marker on the subsets compared to the main B cell
646 populations. **(F)** Heatmap of Spearman correlation coefficient (r_s) and scatterplot of
647 correlation between PBs and mem/DN^{int}, mem/DN^{low} and mem/DN^{high} subset
648 frequencies of HD (n=8) and SLE (n=10). **(G)** Box and whisker plots of median FI of
649 CD71, CD24, CD11c and frequencies of CD38+ or CD95+ of SLE (triangles, n=10)
650 and HD (dots, n=8) for each DN subset.(test: KWT) **(H)** Frequencies of
651 immunoglobulin isotypes per DN and mem subset, respectively of HD (n=6).
652 (Significance levels: * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$)

653 **Figure 3: CXCR5⁺CD19^{low} populations show an activated phenotype. (A)** CyTOF
654 derived UMAP plots (showing 8841 events per cohort of HD and SLE) of IgD⁻ B cells.
655 Top row shows density plots of HD and SLE. Bottom row shows distribution of gated
656 for DN^{int}, DN^{low} and DN^{high}. **(B)** Frequencies among total CD19⁺ B cells of mem/DN^{int},
657 mem/DN^{low} and mem/DN^{high} of HD (dots, n=18) and patients with SLE (triangles,
658 n=24). Expression of activation markers CD86, CD69 and CD25 by mem/DN^{int},
659 mem/DN^{low} and mem/DN^{high} for **(C)** comparison of subsets (test: MWU) or **(D)** HD vs
660 SLE (test: KWT). Scatter plots show the expression of immune checkpoint molecules
661 for comparison **(E)** in between subsets or **(F)** between HD and SLE. (Data is shown
662 as median + 95%CI of [n(HD/SLE) = 18/24]. (Significance levels: * $p \leq 0.05$, ** $p \leq$
663 0.01, *** $p \leq 0.001$, **** $p \leq 0.0001$)

664 **Figure 4: CD19^{low} (mem/DN^{low}) subsets correlate with plasmablasts upon**
665 **vaccination of healthy individuals with BNT162b2. (A)** Kinetics of B cell subset
666 and PB frequencies of 17 HDs before and 7, 14 and 21 days after first vaccination
667 and 7 days upon boost with BNT162b2 were analyzed using flow cytometry. (KWT:* p
668 ≤ 0.05 , ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$) **(B)** Scatter plots show correlations
669 between certain B cell subsets and PBs frequencies upon BNT162b2 vaccination at
670 certain time points of HDs (n=17). (Spearman correlation: r = Spearman coefficient, * p
671 ≤ 0.05 , ** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$).

672 **Figure 5: Reduced BCR responsiveness in CD19 low subsets. (A)**
673 Phosphorylation kinetics of Syk (Y352) of mem/DN^{int}, mem/DN^{low} and mem/DN^{high}
674 subsets and PB at time points 0, 5, 8 and 15 min in HD (n=8, solid line) and SLE
675 (n=15, dashed line). Data is shown in means \pm standard error of mean (SEM) (test:
676 MWU between HD as SLE for each timepoint) **(B)** Scatter plot of Syk expression of

677 mem/DN^{int}, mem/DN^{low} and mem/DN^{high} subsets of HD (n=8, dots) and patients with
678 SLE (n=15, triangle) (test: KWT).

679 **Figure 6: DN^{low} subsets show a transcriptional expression profile somewhat**
680 **similar to plasmablasts.** Boxplots of Log₂(Counts per million(CPM)) of transcription
681 factors *IRF4*, *PRDM1*, *PAX5*, *XBP1*, *EZH2* and *BCL2L1* depicted for naïve, pre-
682 switched, total memory, PBs and DN subsets (DN^{int}, DN^{low} and DN^{high}) of each 7
683 donors of HD and SLE (test: KWT, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤
684 0.0001).

685 **Supplementary Figure 1: Surface expression patterns on mem^{int}, mem^{low} and**
686 **mem^{high} detected by flow cytometry. (A)** Gating strategy of flow cytometry staining
687 for identification of mem and DN subsets shown for a HD. **(B)** Box and whisker plots
688 of median FI of CD71, CD24, CD11c and frequencies of CD38⁺ or CD95⁺ of HD
689 (n=8) for each subset. **(C)** Box and whisker plots of median FI of PD1 and PD-L1 for
690 each subset. **(D)** Box and whisker plots of median FI of CD71 and frequencies of
691 CD95⁺ and CD38⁺ cells memory subsets for HD (dots, n=8) compared to SLE
692 patients (triangles, n=9). (Significance levels: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p
693 ≤ 0.0001).

694 **Supplementary Figure 2: Activation marker and checkpoint molecule**
695 **expression detected by mass cytometry (A)** Gating strategy of CyTOF. **(B)**
696 Distribution of subsets within IgD⁻CD27⁺ and IgD⁻CD27⁻ **(C)** Scatter plots show
697 expression of CD45RA and CD45RO for comparison in between subsets.**(D)**
698 CD45RA and CD45RO differences between HD and patients with SLE. Scatter plots
699 show expression of PD1 and PD-L1 for comparison in between **(E)** subsets or **(F)**
700 between HD (dots) and SLE patients (triangles). **(G)** Scatter plots show expression of
701 Ki-67 for comparison in between subsets or between HD (dots) and SLE patients
702 (triangles). (Data is shown as median + 95%CI of [n(HD/SLE) = 18/24]. (Significance
703 levels: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001)

704

705 **Supplementary table1: Antibodies for flow cytometry analysis**

target	fluorochrome	Clone	Manufacturer
CD19	Brilliant Violet (BV) 711	SJ25C1	Becton Dickinson
CD27	BV785	L128	Becton Dickinson
CD20	BV510	2H7	Biolegend
IgD	Phycoerythrin(PE)/Dazzle	IA6-2	Biolegend
CD38	Allophycocyanin (APC)-Cyanin7 (Cy7)	HIT	Biolegend
CD3	Brilliant Ultraviolet (BUV) 395	M5E2	Becton Dickinson
CD14	BUV395	UCHT1	Becton Dickinson
CD10	BV510	HI10A	Becton Dickinson
CD24	BV605	ML5	Becton Dickinson
CD11c	BUV737	B-ly6	Becton Dickinson
CXCR5	BV421	RF8B2	Becton Dickinson
CXCR5	PE	51505	R&D System
CD95	PE-Cy7	APO-1/Fas	Invitrogen
CD71	Fluorescein (FITC)	Okt3	eBioscience
CD27	APC	L128	Becton Dickinson
CD19	APC-H7	SJ25C1	Becton Dickinson
CD20	BV510	2H7	Biolegend
CD38	PerCpCy5.5	HIT2	Becton Dickinson
CD3	Pacific Blue (PacB)	UCHT1	Becton Dickinson
CD14	PacB	M5E2	Becton Dickinson
PD1	PE	EH12.2H7	Becton Dickinson
PD-L1	APC	29E2A3	Biolegend
Syk	FITC	4D10	Becton Dickinson
pSyk(Y352)	PE		Becton Dickinson
CD22	APC	S-HCL-1	Becton Dickinson
IgM	BV421	G20-127	Becton Dickinson
IgA	Briliant Blue (BB)515	IS11-8E10	Becton Dickinson
IgG	PeCy7	G18-145	Becton Dickinson


707 **Supplementary table 2: Antibodies for mass cytometry analysis**

antibody	Isotype tag
CD45	Y89
ICOS	Pr141
CD19	Nd142
VISTA	908-Nd143
CD69	Nd144
CD4	Nd145
IgD	Nd146
CD11c	Sm147
CD274/PD-L1	Nd148
CD25	Sm149
CD223/LAG-3	Nd150
CD123	Eu151
TCRgd	Sm152
TIGIT	Eu153
TIM3	Sm154
CD27	Gd155
CD86/B7.2	Gd156
CD137/4-1BB	Gd158
Foxp3	Tb159
CD14	Gd160
CD152/CTLA-4	Dy161
CD8	Dy162
CD272/BTLA	Dy163
CXCR5	Dy164
CD45R0	Ho165
CD155	Er166
CD38	Er167
Ki-67	Er168
CD45RA	Tm169
CD3	Er170
CD226	Yb171
IgM	Yb172
CD162/PSGL	Yb173
HLA-DR	Yb174
CD279/PD-1	Lu175
CD56	Yb176
CD16	Bi209


708

709


A




B



C



D



E




Figure 1
Szelinski et al.









A**B****C****D****E****F****G****H**

Figure 2
Szelinski et al.








A**B****C****D****E****F**

Figure 3
Szelinski et al.

A



B




Figure 4
Szelinski et al.

A

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.25.21257784>; this version posted May 27, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



**B**

Figure 5
Szelenksi et al.




Figure 6
Szelinski et al.